Olabimpe Caroline Badejogbin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olabimpe Caroline Badejogbin has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Isaac O. Ajadi
Department of Physiology, College of Health Sciences, Ladoke Akintola University of Technology, Ogbomoso, Nigeria
2 shared publications - Kehinde Samuel Olaniyi
Cardio/Endo-metabolic and Microbiome Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria
2 shared publications - Mary B. Ajadi
Department of Chemical Pathology, College of Health Sciences, Ladoke Akintola University of Technology, Ogbomoso, Nigeria
2 shared publications - Adesola A. Oniyide
Cardio/Endo-Metabolic and Epigenetics Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria
1 shared publication - Bolanle Iranloye
Department of Physiology, College of Medicine, University of Lagos, Idi-Araba, Lagos 101014, Nigeria
1 shared publication - Chukwubueze L. Atuma
Cardio/Endo-Metabolic and Epigenetics Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by MDPI AG in Endocrines
- Vol. 7 (4) , 58
Sodium Butyrate Attenuates Diabetes-Induced Testicular Dysfunction by Modulating Apoptotic Signaling in Male Wistar Rats
Background: Diabetes in males leads to hyperglycemia-induced oxidative stress and inflammation in the testis, resulting in apoptosis. Diabetes-induced testicular impairment has been linked to the implication with the gut–brain axis. Sodium butyrate, a product of the gut microbiota fermentation process, has been targeted for its anti-diabetic, anti-inflammatory, and antioxidative functions. This research, therefore, explored sodium butyrate as a therapeutic potential intervention in mitigating diabetes-induced testicular dysfunction. Methods: Thirty-five male rats were randomly assigned to five groups after diabetes was confirmed: healthy control (CON), sodium butyrate-treated (SBUT; 200 mg/kg orally), diabetic control (T1DM; 50 mg/kg STZ intraperitoneally), diabetes + sodium butyrate (T1DM + SBUT), and diabetes + insulin (T1DM + INSL, 0.9 I.U/100 g/day). Body weight, testicular weight, glucose homeostasis (fasting blood sugar, oral glucose tolerance, and glycated hemoglobin), lipid profile, testosterone level, sperm analysis, histopathology of the testis, and anti-apoptotic markers (B-cell lymphoma-2 (Bcl-2), Bcl-associated protein X (Bax), and Caspase-3) were all assessed. Results: Along with elevated blood glucose and glycated hemoglobin levels, diabetic rats showed a notable decrease in body weight, testicular mass, gonadosomatic index, sperm count, motility, viability, and normal morphology. Elevated Bax and Caspase-3 expression with reduced Bcl-2 were observed alongside testicular fibrosis, accumulation of collagen, and carbohydrate-rich substances. Sodium butyrate treatment, by downregulating Bax and Caspase-3 and upregulating Bcl-2, conserved testicular histoarchitecture, restored sperm quality, controlled apoptotic signaling, and markedly improved metabolic indices. Conclusions: Sodium butyrate displayed a protective role in the testis in diabetic conditions via the modulation of hyperglycemia-induced apoptosis, identifying this as a potential therapeutic intervention in diabetes-induced testicular dysfunction.
- 30 September 2026
- Published by MDPI AG in Endocrines
- Vol. 7 (4) , 58
Open AccessSodium Butyrate Attenuates Diabetes-Induced Testicular Dysfunction by Modulating Apoptotic Signaling in Male Wistar Rats
Background: Diabetes in males leads to hyperglycemia-induced oxidative stress and inflammation in the testis, resulting in apoptosis. Diabetes-induced testicular impairment has been linked to the implication with the gut–brain axis. Sodium butyrate, a product of the gut microbiota fermentation process, has been targeted for its anti-diabetic, anti-inflammatory, and antioxidative functions. This research, therefore, explored sodium butyrate as a therapeutic potential intervention in mitigating diabetes-induced testicular dysfunction. Methods: Thirty-five male rats were randomly assigned to five groups after diabetes was confirmed: healthy control (CON), sodium butyrate-treated (SBUT; 200 mg/kg orally), diabetic control (T1DM; 50 mg/kg STZ intraperitoneally), diabetes + sodium butyrate (T1DM + SBUT), and diabetes + insulin (T1DM + INSL, 0.9 I.U/100 g/day). Body weight, testicular weight, glucose homeostasis (fasting blood sugar, oral glucose tolerance, and glycated hemoglobin), lipid profile, testosterone level, sperm analysis, histopathology of the testis, and anti-apoptotic markers (B-cell lymphoma-2 (Bcl-2), Bcl-associated protein X (Bax), and Caspase-3) were all assessed. Results: Along with elevated blood glucose and glycated hemoglobin levels, diabetic rats showed a notable decrease in body weight, testicular mass, gonadosomatic index, sperm count, motility, viability, and normal morphology. Elevated Bax and Caspase-3 expression with reduced Bcl-2 were observed alongside testicular fibrosis, accumulation of collagen, and carbohydrate-rich substances. Sodium butyrate treatment, by downregulating Bax and Caspase-3 and upregulating Bcl-2, conserved testicular histoarchitecture, restored sperm quality, controlled apoptotic signaling, and markedly improved metabolic indices. Conclusions: Sodium butyrate displayed a protective role in the testis in diabetic conditions via the modulation of hyperglycemia-induced apoptosis, identifying this as a potential therapeutic intervention in diabetes-induced testicular dysfunction.
- Open Access
- 26 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1)
Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that significantly increases cardiovascular disease (CVD) risk in women. While insulin resistance and dyslipidemia are established contributors, growing evidence highlights mitochondrial dysfunction and chronic low‐grade inflammation as central drivers of cardiovascular pathology in PCOS. Objective: This narrative review synthesizes current evidence on how mitochondrial dysfunction and inflammation interact to promote cardiovascular complications in women with PCOS while identifying potential therapeutic targets and areas requiring further investigation. Methods: A comprehensive review of clinical and experimental studies was conducted using PubMed, Scopus, and Web of Science databases. Relevant literature exploring mitochondrial alterations, oxidative stress, inflammatory cytokines, and endothelial function in PCOS, with emphasis on cardiovascular outcomes, was critically evaluated and summarized. Results: Women with PCOS exhibit altered mitochondrial dynamics, reduced ATP production, and elevated reactive oxygen species (ROS), which collectively impair vascular function. These mitochondrial abnormalities compromise oocyte quality and endometrial receptivity and activate proinflammatory signaling pathways, including the NLRP3 inflammasome, contributing to endothelial dysfunction and atherogenesis, and increased long‐term cardiovascular risk, particularly in women with prior pregnancy complications. Elevated levels of cytokines including TNF‐ α , IL‐6, and CRP further exacerbate cardiovascular risk. This bidirectional relationship between mitochondrial dysfunction and inflammation establishes a vicious cycle underlying cardiovascular deterioration in PCOS. Conclusion: Mitochondrial dysfunction and inflammation are interdependent mechanisms that contribute substantially to cardiovascular risk in women with PCOS. Targeting mitochondrial dysfunction and systemic inflammation presents a promising therapeutic strategy for reducing cardiovascular morbidity in PCOS. Future research should emphasize phenotype‐specific interventions, biomarker discovery, and translational trials to improve long‐term reproductive and cardiovascular outcomes.
- 26 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1)
Open AccessCardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that significantly increases cardiovascular disease (CVD) risk in women. While insulin resistance and dyslipidemia are established contributors, growing evidence highlights mitochondrial dysfunction and chronic low‐grade inflammation as central drivers of cardiovascular pathology in PCOS. Objective: This narrative review synthesizes current evidence on how mitochondrial dysfunction and inflammation interact to promote cardiovascular complications in women with PCOS while identifying potential therapeutic targets and areas requiring further investigation. Methods: A comprehensive review of clinical and experimental studies was conducted using PubMed, Scopus, and Web of Science databases. Relevant literature exploring mitochondrial alterations, oxidative stress, inflammatory cytokines, and endothelial function in PCOS, with emphasis on cardiovascular outcomes, was critically evaluated and summarized. Results: Women with PCOS exhibit altered mitochondrial dynamics, reduced ATP production, and elevated reactive oxygen species (ROS), which collectively impair vascular function. These mitochondrial abnormalities compromise oocyte quality and endometrial receptivity and activate proinflammatory signaling pathways, including the NLRP3 inflammasome, contributing to endothelial dysfunction and atherogenesis, and increased long‐term cardiovascular risk, particularly in women with prior pregnancy complications. Elevated levels of cytokines including TNF‐ α , IL‐6, and CRP further exacerbate cardiovascular risk. This bidirectional relationship between mitochondrial dysfunction and inflammation establishes a vicious cycle underlying cardiovascular deterioration in PCOS. Conclusion: Mitochondrial dysfunction and inflammation are interdependent mechanisms that contribute substantially to cardiovascular risk in women with PCOS. Targeting mitochondrial dysfunction and systemic inflammation presents a promising therapeutic strategy for reducing cardiovascular morbidity in PCOS. Future research should emphasize phenotype‐specific interventions, biomarker discovery, and translational trials to improve long‐term reproductive and cardiovascular outcomes.
- 12 March 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (3) , 1-10
Probiotics ameliorates hypothalamic amenorrhea in a rat model of PCOS
Background: Polycystic ovary syndrome (PCOS) is a common endocrinometabolic disorder affecting women of reproductive age, characterized by hormonal imbalances, irregular menstrual cycles, and often, infertility. Hypothalamic amenorrhea, a condition marked by the cessation of menstruation due to disruptions in the hypothalamic-pituitary-gonadal axis, is a frequent manifestation in PCOS. Probiotics, beneficial microorganisms known for improving metabolic health, have shown promise in restoring hormonal balance and enhancing fertility. In this study, we hypothesize that probiotics would ameliorate hypothalamic amenorrhea by modulating hypothalamic kisspeptin and reducing inflammation in a rat model of PCOS. Methods: Eight (8)-week-old female Wistar rats were grouped into four with n = 5. Letrozole administration (1 mg/kg, p.o.) for 21 days induced PCOS, thereafter the animals were treated with probiotics (3 × 109 CFU, p.o.), while control animals received distilled water. The treatment lasted for six weeks. Results: Reduced insulin sensitivity, hyperinsulinemia, ovarian dysfunction with evidence of disrupted steroid hormone levels (testosterone/17β-Estradiol) and cystic follicles as well as hypothalamic lipid accumulation, elevated inflammatory markers (NF-kB/TNF-α) and antioxidant depletion (GSH/NrF2), which are accompanied by decreased level of kisspeptin. Nonetheless, administration of probiotics reversed these pathological alterations by enhancement of hypothalamic kisspeptin and suppression of inflammatory response. Conclusions: Altogether, the present results demonstrate that probiotics significantly ameliorated hypothalamic amenorrhea by mitigating hypothalamic lipid accumulation, suppressed inflammation, and replenished antioxidants. Crucially, probiotics enhanced hypothalamic kisspeptin levels, a key regulator of reproductive function, highlighting their potential as a therapeutic strategy for restoring ovarian function in PCOS. Graphical abstract Graphical abstract showing the ameliorative effect of probiotics on hypothalamic amenorrhea in letrozole-induced PCOS rat model. Gonadotropin releasing hormone (GnRH); Follicle stimulating hormone (FSH); Luteinizing hormone (LH).
- 12 March 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (3) , 1-10
Probiotics ameliorates hypothalamic amenorrhea in a rat model of PCOS
Background: Polycystic ovary syndrome (PCOS) is a common endocrinometabolic disorder affecting women of reproductive age, characterized by hormonal imbalances, irregular menstrual cycles, and often, infertility. Hypothalamic amenorrhea, a condition marked by the cessation of menstruation due to disruptions in the hypothalamic-pituitary-gonadal axis, is a frequent manifestation in PCOS. Probiotics, beneficial microorganisms known for improving metabolic health, have shown promise in restoring hormonal balance and enhancing fertility. In this study, we hypothesize that probiotics would ameliorate hypothalamic amenorrhea by modulating hypothalamic kisspeptin and reducing inflammation in a rat model of PCOS. Methods: Eight (8)-week-old female Wistar rats were grouped into four with n = 5. Letrozole administration (1 mg/kg, p.o.) for 21 days induced PCOS, thereafter the animals were treated with probiotics (3 × 109 CFU, p.o.), while control animals received distilled water. The treatment lasted for six weeks. Results: Reduced insulin sensitivity, hyperinsulinemia, ovarian dysfunction with evidence of disrupted steroid hormone levels (testosterone/17β-Estradiol) and cystic follicles as well as hypothalamic lipid accumulation, elevated inflammatory markers (NF-kB/TNF-α) and antioxidant depletion (GSH/NrF2), which are accompanied by decreased level of kisspeptin. Nonetheless, administration of probiotics reversed these pathological alterations by enhancement of hypothalamic kisspeptin and suppression of inflammatory response. Conclusions: Altogether, the present results demonstrate that probiotics significantly ameliorated hypothalamic amenorrhea by mitigating hypothalamic lipid accumulation, suppressed inflammation, and replenished antioxidants. Crucially, probiotics enhanced hypothalamic kisspeptin levels, a key regulator of reproductive function, highlighting their potential as a therapeutic strategy for restoring ovarian function in PCOS. Graphical abstract Graphical abstract showing the ameliorative effect of probiotics on hypothalamic amenorrhea in letrozole-induced PCOS rat model. Gonadotropin releasing hormone (GnRH); Follicle stimulating hormone (FSH); Luteinizing hormone (LH).
- 16 November 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (6) , 1275-1287
Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome
Purpose Polycystic ovarian syndrome (PCOS) has been associated with cardiovascular risks and comorbid pathologies, particularly cardiorenal disorder. Short-chain fatty acids (SCFAs), especially butyrate, are essential fatty acids that regulate metabolic health and ameliorate granulosa inflammation in PCOS. However, the effect of butyrate on cardiorenal damage associated with PCOS is unknown. This study investigated the impact of SCFA and butyrate on cardiorenal abnormalities in PCOS rat model and the probable involvement of paraoxonase-1 (PON-1). Methods Eight-week-old female Wistar rats were allotted into three groups, n = 5, namely control (CTL), PCOS (LEZ), and LEZ + BUT. Induction of PCOS with letrozole (1 mg/kg) lasted for 21 days, while treatment with butyrate (200 mg/kg) commenced after the induction and lasted for 6 weeks uninterruptedly. Results PCOS rats showed hyperandrogenism, multiple ovarian cysts, disrupted metabolic indices (fasting insulin and homeostatic model of insulin resistance), and increased (p < 0.05) plasma troponin T, urea, and creatinine, as well as increased cardiac/renal stroma cell–derived factor-1/caspase-6, malondialdehyde/nuclear factor-kappaB, transforming growth factor-β1, and renal ϒ-glutamyl transferase, while a significant decrease (p < 0.05) in systemic nitric oxide/endothelial nitric oxide synthase and cardiac/renal hypoxia-inducible factor-1α and nuclear factor erythroid 2–related factor 2, which were accompanied with a decreased level of PON-1. These systemic and cardiorenal derangements were reversed by butyrate administration. Conclusions The results demonstrate the therapeutic benefits of SCFAs, butyrate, against cardiorenometabolic disorder in a model of PCOS. This beneficial effect is accompanied by an elevated level of PON-1. The present data possibly provides a preclinical relevance for the management of cardiorenal syndrome in PCOS.
- 16 November 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (6) , 1275-1287
Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome
Purpose Polycystic ovarian syndrome (PCOS) has been associated with cardiovascular risks and comorbid pathologies, particularly cardiorenal disorder. Short-chain fatty acids (SCFAs), especially butyrate, are essential fatty acids that regulate metabolic health and ameliorate granulosa inflammation in PCOS. However, the effect of butyrate on cardiorenal damage associated with PCOS is unknown. This study investigated the impact of SCFA and butyrate on cardiorenal abnormalities in PCOS rat model and the probable involvement of paraoxonase-1 (PON-1). Methods Eight-week-old female Wistar rats were allotted into three groups, n = 5, namely control (CTL), PCOS (LEZ), and LEZ + BUT. Induction of PCOS with letrozole (1 mg/kg) lasted for 21 days, while treatment with butyrate (200 mg/kg) commenced after the induction and lasted for 6 weeks uninterruptedly. Results PCOS rats showed hyperandrogenism, multiple ovarian cysts, disrupted metabolic indices (fasting insulin and homeostatic model of insulin resistance), and increased (p < 0.05) plasma troponin T, urea, and creatinine, as well as increased cardiac/renal stroma cell–derived factor-1/caspase-6, malondialdehyde/nuclear factor-kappaB, transforming growth factor-β1, and renal ϒ-glutamyl transferase, while a significant decrease (p < 0.05) in systemic nitric oxide/endothelial nitric oxide synthase and cardiac/renal hypoxia-inducible factor-1α and nuclear factor erythroid 2–related factor 2, which were accompanied with a decreased level of PON-1. These systemic and cardiorenal derangements were reversed by butyrate administration. Conclusions The results demonstrate the therapeutic benefits of SCFAs, butyrate, against cardiorenometabolic disorder in a model of PCOS. This beneficial effect is accompanied by an elevated level of PON-1. The present data possibly provides a preclinical relevance for the management of cardiorenal syndrome in PCOS.